n Cardiovascular Journal of South Africa - Comment on generic anti-arrhythmic drugs : letter to the editor

Volume 13, Issue 3
  • ISSN : 1680-0745



Extracted from text ... To the Editor: The management of cardiac arrhythmias is difficult and fraught with complications. Anti-arrhythmic medications have a narrow therapeutic window; too high a level could result in pro-arrhythmic effects and too low a level could result in recurrence of the arrhythmia. Sanofi-Synthelabo is the manufacturer of the original amiodarone, Cordarone(r), and has over 30 years of clinical research data and clinical experience regarding the antiarrhythmic effect of this product. Among recently published trials are: CTAF1 and AFIST:2 two large trials looking at the safety and efficacy of Cordarone(r) in supraventricular tachycardia. ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error